Assoc. Prof. Nuri Alper Şahbaz is an experienced doctor with medical education from Istanbul University, Cerrahpaşa Faculty of Medicine, and scientific and clinical experience from Baylor College of Medicine and The University of Texas Medical School. He is specialized in endocrine surgery (thyroid, parathyroid, adrenal gland and neuroendocrine tumors) and has performed over 2000 successful surgeries in this area. He also specializes in laparoscopic and minimally invasive surgeries, as well as in diagnostic and therapeutic gastrointestinal system endoscopy.
Read moreAssoc. Prof. Nuri Alper Şahbaz is an experienced doctor with medical education from Istanbul University, Cerrahpaşa Faculty of Medicine, and scientific and clinical experience from Baylor College of Medicine and The University of Texas Medical School. He is specialized in endocrine surgery (thyroid, parathyroid, adrenal gland and neuroendocrine tumors) and has performed over 2000 successful surgeries in this area. He also specializes in laparoscopic and minimally invasive surgeries, as well as in diagnostic and therapeutic gastrointestinal system endoscopy.
Specializations
Cancer Surgery
Pancreatic Surgery
Bile Duct Surgery
Bariatric Metabolic Surgery
Oncological Surgery
Breast Surgery
Gastric cancer
Colon cancer
Thyroid Cancer
Obesity Surgery
Diabetes Surgeries
Read more
Specializations
Cancer Surgery
Pancreatic Surgery
Bile Duct Surgery
Bariatric Metabolic Surgery
Oncological Surgery
Breast Surgery
Gastric cancer
Colon cancer
Thyroid Cancer
Obesity Surgery
Diabetes Surgeries
Education and Experience
Education and Experience
Education:
Roles in Projects:
Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.
Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.
Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.
Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).
Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Read moreEducation:
Roles in Projects:
Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.
Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.
Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.
Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).
Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.